Fresenius Kabi and Octapharma Group enter into an Exclusive Agreement for a HESylated recombinant protein
Advertisement
Fresenius Kabi and Octapharma Group have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi’s HESylation® Technology to develop a HESylated recombinant protein.
Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch (“HES”) which will be combined with a recombinant protein from Octapharma’s human cell-line platform – this combination is intended to generate a therapeutic protein with a superior product profile.
Fresenius Kabi will seek to adapt and optimize the protein modification by its HESylation® Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma. Under the agreement, Octapharma will oversee the further development and commercialization. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation® Technology.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Pepscan Therapeutics closes a Research and License Agreement aimed at the development of novel vaccines
United_States_Environmental_Protection_Agency
Antimicrobial_pharmacodynamics
Nymox Announces New Positive Results from 3 1/2 Year Study of NX-1207 for Benign Prostatic Hyperplasia
Laparoscopic_surgery
Category:Glands
ExonHit Announces Termination of Agreement to Acquire RedPath

Coffee drinking is associated with increased longevity - "It is likely that the non-caffeinated compounds were responsible for the positive relationships observed between coffee drinking, cardiovascular disease and survival"
GE Healthcare acquires bioprocessing start-up - Obtaining nanofiber-based platform purification technology for biopharmaceutical production
Evotec to Acquire Renovis - Merger to Create Emerging Pharmaceutical Company
